Abstract Purpose of Review Severe coronavirus disease 2019 (COVID-19) is characterized
by the development of a deleterious hyperinflammatory response, in which the pleiotropic …

This retrospective matched cohort study describes 30 solid organ transplant (SOT) patients
with Coronavirus Disease 2019 (COVID‐19) matched 1: 2 to 60 non‐SOT patients (control …

Acute respiratory distress syndrome associated with coronavirus infection is related to a
cytokine storm with large interleukin‐6 (IL‐6) release. The IL‐6‐receptor blocker tocilizumab …

There are emerging data depicting the clinical presentation of coronavirus disease 19
(COVID-19) in solid organ transplant recipients but negligible data-driven guidance on …

Background The aim of this study was to assess the effect of continuing immune suppressive
therapy in solid organ transplant recipients (SOTR) with coronavirus disease 2019 (COVID …

As in the general population with coronavirus 2019 (COVID-19) infection, therapeutic
interventions in solid organ transplant (SOT) recipients have evolved over time. The …

The novel coronavirus, SARS-CoV-2, is causing a pandemic of unknown precedent, with
huge healthcare challenges and worldwide disruptions to economic and social life. Lung …

The novel coronavirus disease 2019 (COVID‐19) is a highly infectious and rapidly
spreading disease. There are limited published data on the epidemiology and outcomes of …

Background Current guidelines recommend immunomodulators, tocilizumab or baricitinib,
for the management of severe coronavirus disease‐2019 (COVID‐19) in patients with …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
is challenging health systems all over the world. Particularly high-risk groups show …